XL-protein is a privatly owned German biotech company commercializing the revolutionary PASylation technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. With its strong proprietary technology position, including a broad basis of preclinical data, XL-protein focuses at the preclinical as well clinical development of PASylated proteins in several disease areas.
XL-protein’s goal is to provide improved second generation biopharmaceuticals allowing less frequent and lower dosing together with better tolerability, thus making treatment cheaper and supporting patient compliance and safety.
XL-protein was founded in 2009 as a spin-off from the Insitute of Biological Chemistry at the Technische Universität München (TUM). The company is located at Freising, situated in the neighbourhood of Munich international airport as well as the TUM life science campus Freising-Weihenstephan.